Dyslipidemia

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · see citing works

Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity

Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860 · see citing works

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026 · see citing works

Health benefits of physical activity: the evidence

Warburton, D. E. R. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.051351 · Cited by 8,007 · see citing works

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · see citing works

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992 · see citing works

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848 · see citing works

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · see citing works

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550 · see citing works

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · see citing works

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261 · see citing works

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · see citing works

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · see citing works

Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia

Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881 · see citing works

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · see citing works

Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease

LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489 · see citing works

Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol

Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · see citing works

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284 · see citing works

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911 · see citing works

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · see citing works

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · see citing works

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479 · see citing works

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · see citing works

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis

Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081 · see citing works

Effects of Exercise on Glycemic Control and Body Mass in Type 2 Diabetes Mellitus: A Meta-analysis of Controlled Clinical Trials

Boulé, N. G., Haddad, E., Kenny, G. P., Wells, G. A., & Sigal, R. J. (2001) · JAMA · doi:10.1001/jama.286.10.1218 · Cited by 1,889 · see citing works

Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association

Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871 · see citing works

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828 · see citing works

Effects of extended-release niacin with laropiprant in high-risk patients

The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · see citing works

Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623 · see citing works

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509 · see citing works

Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis

Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390 · see citing works

Effects of medical therapies on retinopathy progression in type 2 diabetes

The ACCORD Study Group and ACCORD Eye Study Group (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001288 · Cited by 1,311 · see citing works

Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes

and the WHO Multinational Study Group, Morrish, N. J., Wang, S.-L., Stevens, L. K., Fuller, J. H., & Keen, H. (2001) · Diabetologia · doi:10.1007/pl00002934 · Cited by 1,288 · see citing works

Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study

(2000) · Circulation · doi:10.1161/01.cir.102.1.21 · Cited by 1,273 · see citing works

High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study

Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,227 · see citing works

2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult

Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Grover, S., Gupta, M., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.510 · Cited by 1,173 · see citing works

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

Tominaga, M., Eguchi, H., Manaka, H., Igarashi, K., Kato, T., & Sekikawa, A. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.920 · Cited by 1,165 · see citing works

Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis

Dattilo, A., & Kris-Etherton, P. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.2.320 · Cited by 1,055 · see citing works

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 933 · see citing works

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study

McQueen, M. J., Hawken, S., Wang, X., Ounpuu, S., Sniderman, A., Probstfield, J., Steyn, K., Sanderson, J. E., Hasani, M., Volkova, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61076-4 · Cited by 864 · see citing works

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

Steiner, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04209-4 · Cited by 845 · see citing works

Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study

Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844 · see citing works

The Burden of Mortality Attributable to Diabetes

Roglić, G., Unwin, N. C., Bennett, P. H., Mathers, C. D., Tuomilehto, J. O., Nag, S., Connolly, V. M., & King, H. O. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2130 · Cited by 809 · see citing works

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792 · see citing works

2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

Anderson, T. J., Grégoire, J. C., Hegele, R. A., Couture, P., Mancini, G. B. J., McPherson, R., Francis, G. A., Poirier, P., Lau, D. C. W., Grover, S. A., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.11.032 · Cited by 762 · see citing works

Low Cardiorespiratory Fitness and Physical Inactivity as Predictors of Mortality in Men with Type 2 Diabetes

Wei, M., Gibbons, L. W., Kampert, J. B., Nichaman, M. Z., & Blair, S. N. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-8-200004180-00002 · Cited by 709 · see citing works

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Swerdlow, D. I., Preiss, D., Kuchenbaecker, K. B., Holmes, M. V., Engmann, J. E. L., Shah, T., Sofat, R., Stender, S., Johnson, P. C. D., Scott, R. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61183-1 · Cited by 680 · see citing works

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Sabatine, M. S., Leiter, L. A., Wiviott, S. D., Giugliano, R. P., Deedwania, P., De Ferrari, G. M., Murphy, S. A., Kuder, J. F., Gouni-Berthold, I., Lewis, B. S., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30313-3 · Cited by 603 · see citing works

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 575 · see citing works

Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes

Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550 · see citing works

The Impact of Diabetes Mellitus on Mortality From All Causes and Coronary Heart Disease in Women

Hu, F. B., Stampfer, M. J., Solomon, C. G., Liu, S., Willett, W. C., Speizer, F. E., Nathan, D. M., & Manson, J. E. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.14.1717 · Cited by 526 · see citing works

Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk

Griffin, B. A., Freeman, D. J., Tait, G. W., Thomson, J., Caslake, M. J., Packard, C. J., & Shepherd, J. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90129-5 · Cited by 525 · see citing works

The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

Girman, C. J., Rhodes, T., Mercuri, M. F., Pyörälà, K., KJEKSHUS, J. K., Pedersen, T. R., Beere, P. A., Gotto, A. M., & Clearfield, M. B. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.09.028 · Cited by 525 · see citing works

Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2465 · Cited by 525 · see citing works

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

McKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 507 · see citing works

ACC/AHA/NHLBI clinical advisory on the use and safety of statins11When citing this document, the American College of Cardiology, American Heart Association, and National Heart, Lung and Blood Institute would appreciate the following citation format: Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Advisory on the Use and Safety of Statins. J Am Coll Cardiol 2002;40:568–73.22This document is available on the Web sites of the ACC (www.acc.org), the AHA (www.americanheart.org), and the NHLBI (www.nhlbi.nih.gov/guidelines/cholesterol).

Pasternak, R. C., Smith, S. C., Merz, C. N. B., Grundy, S. M., Cleeman, J. I., & Lenfant, C. J. M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02030-2 · Cited by 497 · see citing works

Exercise capacity and body composition as predictors of mortality among men with diabetes

Church, T. S., Cheng, Y. J., Earnest, C. P., Barlow, C. E., Gibbons, L. W., Priest, E. L., & Blair, S. N. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.83 · Cited by 469 · see citing works

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel

Barter, P. J., Ballantyne, C. M., Carmena, R., Cabezas, M. C., Chapman, M. J., Couture, P., Graaf, J. D., Durrington, P. N., Færgeman, O., Frohlich, J., et al. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01616.x · Cited by 463 · see citing works

Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis

Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., & Ridker, P. M. (2009) · Diabetes Care · doi:10.2337/dc09-0738 · Cited by 439 · see citing works

Lipoprotein Heterogeneity and Apolipoprotein B Metabolism

Packard, C. J., & Shepherd, J. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.12.3542 · Cited by 401 · see citing works

Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes

Sever, P. S., Poulter, N. R., Dahlöf, B., Wedel, H., Collins, R., Beevers, G., Caulfield, M., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1151 · Cited by 390 · see citing works

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study

Deedwania, P., Barter, P., Carmena, R., Fruchart, J.-C., Grundy, S. M., Haffner, S., Kastelein, J. J., LaRosa, J. C., Schachner, H., Shepherd, J., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69292-1 · Cited by 387 · see citing works

Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies

Evans, J. M. M., Wang, J., & Morris, A. D. (2002) · BMJ · doi:10.1136/bmj.324.7343.939 · Cited by 384 · see citing works

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

on behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371 · see citing works

Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk

Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368 · see citing works

Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.

Genest, J. J., Frohlich, J. J., Fodor, G. J., & McPherson, R. (2003) · PubMed Central · Cited by 345 · see citing works

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials

Costa, J., Borges, M., David, C., & Carneiro, A. V. (2006) · BMJ · doi:10.1136/bmj.38793.468449.ae · Cited by 340 · see citing works

The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus

Ginsberg, H. N., & MacCallum, P. R. (2009) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00044.x · Cited by 331 · see citing works

Insulin Resistance and Cardiovascular Events With Low HDL Cholesterol

Robins, S. J., Bloomfield, H. E., Faas, F. H., Schaefer, E. J., Elam, M. B., Anderson, J. W., Collins, D. E., & on behalf of the VA-HIT Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1513 · Cited by 308 · see citing works

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.

Athyros, V., Papageorgiou, A., Athyrou, V., Demitriadis, D., & Kontopoulos, A. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1198 · Cited by 277 · see citing works

Cardiovascular Outcomes in Type 2 Diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study

Elkeles, R. S., Diamond, J. R., Poulter, C., Dhanjil, S. K., Nicolaides, A. N., Mahmood, S., Richmond, W., Mather, H. M., Sharp, P. S., Feher, M. D., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.641 · Cited by 270 · see citing works

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260 · see citing works

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial

Margolis, K. L., O’Connor, P. J., Morgan, T. M., Buse, J. B., Cohen, R. M., Cushman, W. C., Cutler, J. A., Evans, G. W., Gerstein, H. C., Grimm, R. H., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2334 · Cited by 259 · see citing works

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)

Mancini, G. B. J., Baker, S. K., Bergeron, J., FITCHETT, D. H., Frohlich, J. J., Genest, J. J., Gupta, M., Hegele, R. A., Ng, D. S., Pearson, G. J., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.01.003 · Cited by 253 · see citing works

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis

Lee, M., Saver, J. L., Towfighi, A., Chow, J., & Ovbiagele, B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.020 · Cited by 240 · see citing works

Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study)

Harris, S. B., Ékoé, J.-M., Zdanowicz, Y., & Webster-Bogaert, S. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.024 · Cited by 237 · see citing works

New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders

McKenney, J. M. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.7.697 · Cited by 216 · see citing works

Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis

Bruckert, E., Labreuche, J., Deplanque, D., Touboul, P.-J., & Amarenco, P. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318202709f · Cited by 192 · see citing works

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference

Mancini, G. B. J., Baker, S. K., Bergeron, J., FITCHETT, D. H., Frohlich, J. J., Genest, J. J., Gupta, M., Hegele, R. A., Ng, D. S., & Pope, J. E. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.05.007 · Cited by 184 · see citing works

Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group

Leiter, L. A., FITCHETT, D. H., Gilbert, R. E., Gupta, M., Mancini, G. B. J., McFarlane, P. A., Ross, R., Teoh, H., Verma, S., Anand, S. S., et al. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2010.12.054 · Cited by 184 · see citing works

Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia

Jenkins, D. J., Kendall, C. W., Faulkner, D. A., Nguyen, T., Kemp, T., Marchie, A., Wong, J. M., de Souza, R., Emam, A., Vidgen, E., et al. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn.83.3.582 · Cited by 184 · see citing works

Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update

Mancini, G. B. J., Tashakkor, A. Y., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D. S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.09.023 · Cited by 173 · see citing works

Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study

Sandhu, S., Al-Sarraf, A., Taraboanta, C., Frohlich, J., & Francis, G. A. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-157 · Cited by 167 · see citing works

Insulin-dependent Diabetes Mellitus, Physical Activity, and Death

Moy, C. S., Songer, T. J., LaPorte, R. E., Dorman, J. S., Kriska, A. M., Orchard, T. J., BECKER, D. J., & DRASH, A. L. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116604 · Cited by 160 · see citing works

Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification

Ramjee, V., Sperling, L. S., & Jacobson, T. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.009 · Cited by 157 · see citing works

Comprehensive Cardiovascular Risk Factor Control Improves Survival

Bittner, V., Bertolet, M. H., Barraza, R., Farkouh, M. E., Goldberg, S., Ramanathan, K. B., Redmon, J. B., Sperling, L. S., & Rutter, M. K. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.019 · Cited by 129 · see citing works

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia

Durrington, P. N., Tuomilehto, J. O., Hamann, A., Kallend, D. G., & Smith, K. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2003.11.012 · Cited by 111 · see citing works

On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy

Mora, S., Glynn, R. J., Boekholdt, S. M., Nordestgaard, B. G., Kastelein, J. J. P., & Ridker, P. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.035 · Cited by 107 · see citing works

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)

Charlton-Menys, V., Betteridge, D. J., Colhoun, H., Fuller, J., France, M., Hitman, G. A., Livingstone, S. J., Neil, H. A. W., Newman, C. B., Szarek, M., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.111401 · Cited by 94 · see citing works

The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials

Coleman, C. I., Reinhart, K. M., Kluger, J., & White, C. M. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x292029 · Cited by 90 · see citing works

A Dietary portfolio: Maximal reduction of low-density lipoprotein cholesterol with diet

Kendall, C. W. C., & Jenkins, D. J. A. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0091-9 · Cited by 88 · see citing works

Evidence-Based Diabetes Care

Herman, W. H. (2002) · Clinical Diabetes · doi:10.2337/diaclin.20.1.22 · Cited by 87 · see citing works

Lipid‐altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials

Leiter, L. A., Betteridge, D. J., Farnier, M., Guyton, J. R., Lin, J., Shah, A., Johnson‐Levonas, A. O., & Brudi, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01383.x · Cited by 84 · see citing works

Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence

Hermans, M. P., Sacks, F. M., Ahn, S. A., & Rousseau, M. F. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-20 · Cited by 83 · see citing works

Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From <i>ATVB</i> Council

Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63 · see citing works

Efficacy of Standard and Intensive Statin Treatment for the Secondary Prevention of Cardiovascular and Cerebrovascular Events in Diabetes Patients: A Meta-Analysis

de Vries, F. M., Kolthof, J., Postma, M. J., Denig, P., & Hak, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111247 · Cited by 56 · see citing works

Pathophysiology of diabetic dyslipidemia:implications for atherogenesis and treatment

Sugden, M., & Holness, M. (2011) · Clinical Lipidology · doi:10.2217/clp.11.32 · Cited by 55 · see citing works

Statin diabetogenicity: guidance for clinicians

Ray, K. K. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-s1-s3 · Cited by 55 · see citing works

Metabolic Dyslipidemia and Risk of Coronary Heart Disease in 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol &lt;100 mg/dl

Rana, J. S., Liu, J. Y., Moffet, H. H., Solomon, M. D., Go, A. S., Jaffe, M. G., & Karter, A. J. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.08.039 · Cited by 50 · see citing works

The High-Density Lipoprotein Puzzle

Rosenson, R. S. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307024 · Cited by 44 · see citing works

Diabetes Mellitus and Cardiovascular Events in Older Patients With Myocardial Infarction Prescribed Intensive-Dose and Moderate-Dose Statins

Ko, D. T., Wijeysundera, H. C., Jackevicius, C. A., Yousef, A., Wang, J., & Tu, J. V. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.000015 · Cited by 39 · see citing works

Lipids, lipid-lowering therapy and diabetes complications

Valensi, P. E., & Picard, S. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.10.001 · Cited by 36 · see citing works

The role of triglycerides in cardiovascular risk

Gandotra, P., & Miller, M. J. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0079-0 · Cited by 32 · see citing works

Prevention of Cardiovascular Disease Utilizing Fibrates-A Pooled Meta-analysis

Loomba, R. S., & Arora, R. R. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181dcf72b · Cited by 30 · see citing works

Simvastatin–ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study

Chang, S., Wu, L., Lee, C., Kuo, C.-T., Liu, J., Wen, M., Chen, W.-J., See, L., & Yeh, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.121 · Cited by 23 · see citing works

The Role of Colesevelam Hydrochloride in Hypercholesterolemia and Type 2 Diabetes Mellitus

Brunetti, L., & DeSantis, E. R. H. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m728 · Cited by 13 · see citing works

Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes

Avitabile, N. A., Banka, A., & Fonseca, V. A. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.548320 · Cited by 13 · see citing works

Association of a reduction in low-density lipoprotein cholesterol with incident cardiovascular and cerebrovascular events among people with type 2 diabetes mellitus

Li, L., Ambegaonkar, B. M., Reckless, J. P. D., & Jick, S. S. (2013) · European Journal of Preventive Cardiology · doi:10.1177/2047487313481752 · Cited by 9 · see citing works

Treatment of dyslipidemia in patients with type 2 diabetes: Overview and meta-analysis of randomized trials

Tkáč, I. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.09.011 · Cited by 7 · see citing works

A meta-analysis of the effects of statin treatment on cardiovascular events and all-cause mortality in diabetic dialysis patients.

Yang, M. G., Xie, X., & Yuan, W. (2015) · PubMed · Cited by 6 · see citing works

A Modern Approach to Dyslipidemia

Berberich, A. J., & Hegele, R. A. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 502 · see citing works

Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association

Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304 · see citing works

Periodontitis and implant complications in diabetes

Nibali, L., Gkranias, N., Mainas, G., & Pino, A. D. (2022) · Periodontology 2000 · doi:10.1111/prd.12451 · Cited by 177 · see citing works

Dyslipidemia, Diabetes and Atherosclerosis: Role of Inflammation and ROS-Redox-Sensitive Factors

Hasheminasabgorji, E., & Jha, J. C. (2021) · Biomedicines · doi:10.3390/biomedicines9111602 · Cited by 126 · see citing works

Management of diabetic dyslipidemia: An update

Jialal, I., & Singh, G. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i5.280 · Cited by 123 · see citing works

Dyslipidemia Management in Adults With Diabetes

Lazarte, J., & Hegele, R. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.07.003 · Cited by 87 · see citing works

Low-level environmental lead and cadmium exposures and dyslipidemia in adults: Findings from the NHANES 2005–2016

Xu, H., Mao, Y., Xu, B., & Hu, Y. (2020) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2020.126651 · Cited by 64 · see citing works

Effects of curcumin/turmeric supplementation on lipid profile: A GRADE-assessed systematic review and dose–response meta-analysis of randomized controlled trials

Dehzad, M. J., Ghalandari, H., Amini, M. R., & Askarpour, M. (2023) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2023.102955 · Cited by 39 · see citing works

The vascular complications of diabetes: a review of their management, pathogenesis, and prevention

Meir, J., Huang, L., Mahmood, S., Whiteson, H. Z., Cohen, S., & Aronow, W. S. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2279533 · Cited by 41 · see citing works

Bile Acid Sequestrants for Hypercholesterolemia Treatment Using Sustainable Biopolymers: Recent Advances and Future Perspectives

Islam, M. S., Sharif, A., Kwan, N., & Tam, K. C. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00007 · Cited by 40 · see citing works

Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians

Butalia, S., Lee-Krueger, R. C. W., McBrien, K. A., Leung, A. A. C., Anderson, T. J., Quan, H., Naugler, C. T., Chen, G., & Campbell, D. J. T. (2020) · CJC Open · doi:10.1016/j.cjco.2020.07.002 · Cited by 37 · see citing works

Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study

Hao, R. C., Myroniuk, T. W., McGuckin, T., Manca, D. P., Campbell-Scherer, D. L., Lau, D., & Yeung, R. O. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01731-w · Cited by 35 · see citing works

The pharmaco-epigenetics of hypertension: a focus on microRNA

Yaacoub, S., Boudaka, A., Alkhatib, A., Pintus, G., Sahebkar, A., Kobeissy, F. H., & Eid, A. H. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-04947-9 · Cited by 31 · see citing works

Potential Effects of Sweet Potato (Ipomoea batatas) in Hyperglycemia and Dyslipidemia—A Systematic Review in Diabetic Retinopathy Context

Naomi, R., Bahari, H., Yazid, M. D., Othman, F., Zakaria, Z. A., & Hussain, M. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910816 · Cited by 30 · see citing works

Diabetic dyslipidaemia

Thambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 33 · see citing works

Saturated fatty acids induce insulin resistance in podocytes through inhibition of IRS1 via activation of both IKKβ and mTORC1

Denhez, B., Rousseau, M., Spino, C., Dancosst, D.-A., Dumas, M.-È., Guay, A., Lizotte, F., & Geraldes, P. (2020) · Scientific Reports · doi:10.1038/s41598-020-78376-1 · Cited by 29 · see citing works

Managing dyslipidemia in patients with Type 2 diabetes

Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 25 · see citing works

The Development of Dyslipidemia in Chronic Kidney Disease and Associated Cardiovascular Damage, and the Protective Effects of Curcuminoids

Ceja-Galicia, Z. A., Aranda‐Rivera, A. K., Amador‐Martínez, I., Aparicio‐Trejo, O. E., Tapia, E., Trujillo, J., Ramírez, V., & Pedraza‐Chaverrí, J. (2023) · Foods · doi:10.3390/foods12050921 · Cited by 25 · see citing works

Cystic Fibrosis–related Diabetes: A First Canadian Clinical Practice Guideline

Coriati, A., Potter, K. J., Gilmour, J. A., Lam, G. Y., Nichols, C., Lands, L. C., Doyle, M.-A., Boudreau, V., Alexandre‐Heymann, L., McKinney, M. L., et al. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.09.001 · Cited by 24 · see citing works

Causal Association of Type 2 Diabetes Mellitus and Glycemic Traits With Cardiovascular Diseases and Lipid Traits: A Mendelian Randomization Study

Huang, M., Laina-Nicaise, L.-D., Zha, L., Tang, T., & Cheng, X. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.840579 · Cited by 24 · see citing works

Cardiac Metabolism, Reprogramming, and Diseases

Wang, H., Shen, M., Shu, X., Guo, B., Jia, T., Feng, J., Lu, Z., Chen, Y., Lin, J. M., Liu, Y., et al. (2023) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-023-10432-3 · Cited by 22 · see citing works

Achievement of treatment targets among patients with type 2 diabetes in 2015 and 2020 in Canadian primary care

Nandiwada, S., Manca, D. P., Yeung, R. O., & Lau, D. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.220673 · Cited by 20 · see citing works

Comparison of Clinical and Social Characteristics of Canadian Youth Living With Type 1 and Type 2 Diabetes

Carino, M., Elia, Y. T., Sellers, E. A. C., Curtis, J., McGavock, J., Scholey, J. W., Hamilton, J. K., Clarson, C. L., Pinto, T. E., Hadjiyannakis, S., et al. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.01.008 · Cited by 20 · see citing works

Therapeutic Effect of Curcumin on 5/6Nx Hypertriglyceridemia: Association with the Improvement of Renal Mitochondrial β-Oxidation and Lipid Metabolism in Kidney and Liver

Ceja-Galicia, Z. A., García‐Arroyo, F. E., Aparicio‐Trejo, O. E., El‐Hafidi, M., Gonzaga, G., León‐Contreras, J. C., Hernández‐Pando, R., Guevara‐Cruz, M., Tovar, A. R., Rojas‐Morales, P., et al. (2022) · Antioxidants · doi:10.3390/antiox11112195 · Cited by 19 · see citing works

Remission of Type 2 Diabetes: User’s Guide

Jin, S., BAJAJ, H. S., Brazeau, A., Champagne, J., MacDonald, B., MacKay, D., Reichert, S. M., Vallis, M., BAJAJ, H. S., Gilbert, J. D., et al. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2022.10.005 · Cited by 17 · see citing works

Prevalence and management of dyslipidemia in primary care practices in Canada

Spohn, O., Morkem, R., Singer, A. G., & Barber, D. (2024) · Canadian Family Physician · doi:10.46747/cfp.7003187 · Cited by 13 · see citing works

The impact of environmental cadmium exposure on type 2 diabetes risk: a protocol for an overview of systematic reviews

Hildebrand, J., Thakar, S., Watts, T.-L., Banfield, L. E., Thabane, L., Macri, J., Hill, S., & Samaan, M. C. (2019) · Systematic Reviews · doi:10.1186/s13643-019-1246-7 · Cited by 11 · see citing works

The Role of VEGF Family in Lipid Metabolism

Zhou, Y., Zhu, X., Wang, H., Duan, C., Cui, H., Shi, J., Shi, S., Yuan, G., & Hu, Y. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023666220506105026 · Cited by 12 · see citing works

Feasibility of identifying and describing the burden of early-onset metabolic syndrome in primary care electronic medical record data: a cross-sectional analysis

Boisvenue, J., Oliva, C. U., Manca, D. P., Johnson, J. A., & Yeung, R. O. (2020) · CMAJ Open · doi:10.9778/cmajo.20200007 · Cited by 11 · see citing works

Research advances in current drugs targeting hyperlipidemia (Review)

Zhao, H., Wang, Y., Li, Y., Cheng, R., & Chen, W. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13623 · Cited by 10 · see citing works

Importance of Dyslipidaemia Treatment in Individuals with Type 2 Diabetes Mellitus—A Narrative Review

Strikić, D., Vujević, A., Perica, D., Leskovar, D., Paponja, K., Pećin, I., & Merćep, I. (2023) · Diabetology · doi:10.3390/diabetology4040048 · Cited by 9 · see citing works

The effects of guar gum supplementation on lipid profile in adults: a GRADE-assessed systematic review, meta-regression and dose–response meta-analysis of randomised placebo-controlled trials

Setayesh, L., Pourreza, S., Khosroshahi, M. Z., Asbaghi, O., Bagheri, R., Kelishadi, M. R., Wong, A., Clark, C. C. T., Ashtary‐Larky, D., Suzuki, K., et al. (2022) · British Journal Of Nutrition · doi:10.1017/s0007114522002136 · Cited by 10 · see citing works

Diabetic dyslipidemia and its predictors among people with diabetes in Ethiopia: systematic review and meta-analysis

Azagew, A. W., Abate, H. K., Mekonnen, C. K., Mekonnen, H. S., Tezera, Z. B., & Belay, G. J. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02593-2 · Cited by 9 · see citing works

Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction)

Soliemanabad, S. K., Rasouli, K., Zakariaei, Z., Soleymani, M., & Aliabadi, P. K. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.103384 · Cited by 9 · see citing works

Diabetes and Metabolic Dysfunction–associated Steatotic Liver Disease in Adults: A Clinical Practice Guideline

Kim, J., BAJAJ, H. S., Ramji, A. S., Bémeur, C., & Sebastiani, G. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.003 · Cited by 8 · see citing works

RSSDI consensus recommendations for dyslipidemia management in diabetes mellitus

Saboo, B., Agarwal, S., Makkar, B. M., Chawla, R., Ghosh, S. K., Viswanathan, V., Gupta, S., Kumar, C. V., Maheshwari, A., Sreenivasamurthy, L., et al. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01063-6 · Cited by 8 · see citing works

Potentially Inappropriate Medications Use among Older Adults with Dyslipidaemia

Alwhaibi, M., & Alkofide, H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12124063 · Cited by 8 · see citing works

Care gaps in achieving cholesterol targets in people with diabetes: A population-based study in a universal health care setting

Butalia, S., Chen, G., Duan, Q., & Anderson, T. J. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109177 · Cited by 6 · see citing works

Best practice for treating dyslipidaemia in patients with diabetes based on current international guidelines

Lan, N. S. R., Burns, K. A., Bell, D. A., & Watts, G. F. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000594 · Cited by 6 · see citing works

Research Progress on Anti-Hyperlipidemia Peptides Derived from Foods

Zhao, M., Qiao, K., Zhang, L., Li, L., Chen, S., Chen, L., & Zhang, Y. (2025) · Nutrients · doi:10.3390/nu17071181 · Cited by 8 · see citing works

CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management

Mancini, G. B. J., CHENG, A. Y. Y., Connelly, K. A., FITCHETT, D. H., Goldenberg, R., Goodman, S. G., Leiter, L. A., Lonn, E., Paty, B. W., Poirier, P., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.07.010 · Cited by 5 · see citing works

Role of Serum Lipids, Blood Glucose and Blood Pressure in Breast Cancer Risk for Women with Type 2 Diabetes Mellitus

Zhang, F., de Bock, G. H., Denig, P., Landman, G. W. D., Zhang, Q., & Sidorenkov, G. A. (2023) · Clinical Epidemiology · doi:10.2147/clep.s386471 · Cited by 5 · see citing works

Dietary Supplements as Modulators of the Nrf2 Pathway to Enhance Intracellular Antioxidant Responses and Protect Against Dyslipidemia-Associated Cardiovascular Complications

Mthembu, S. X. H., Mazibuko-Mbeje, S. E., Silvestri, S., Orlando, P., Nkambule, B. B., Muller, C. J. F., Tiano, L., & Dludla, P. V. (2025) · Food Reviews International · doi:10.1080/87559129.2024.2449378 · Cited by 3 · see citing works

Ações de prevenção e controle de diabetes na atenção primária no Amazonas

de Leon, E. B., Fernandes, L. S., Campos, H. L. M., & Almeida, F. A. (2022) · Revista Brasileira de Atividade Física & Saúde · doi:10.12820/rbafs.27e0271 · Cited by 3 · see citing works

Guardians For Health: A Practical Approach to Improving Quality of Life and Longevity in People with Type 2 Diabetes

Kanumilli, N., Butler, J., Makrilakis, K., Rydén, L., Vallis, M., Wanner, C., Zieroth, S. R., Alhussein, A., & CHENG, A. Y. Y. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01418-0 · Cited by 3 · see citing works

Short-term fenofibrate treatment improves ultrastructure of hepatocytes of old rats

Zubrzycki, A., Wrońska, A., Zauszkiewicz–Pawlak, A., & Kmieć, Z. (2021) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.a2021.0018 · Cited by 3 · see citing works

Effectiveness and Acceptability of a Nutrition Intervention Targeting Chinese Adult Immigrants With Type 2 Diabetes in Canada: A Study Using Mixed-Methods Analysis

Deng, F., Mahmoodi, B., & Chan, C. B. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2022.04.006 · Cited by 3 · see citing works

Environmental Cadmium Exposure and Type 2 Diabetes Mellitus Risk: An Overview of Systematic Reviews

Hildebrand, J., Thakar, S., Watts, T.-L., Banfield, L. E., Thabane, L., Macri, J., Hill, S., & Samaan, M. C. (2022) · Exposure and Health · doi:10.1007/s12403-021-00449-x · Cited by 2 · see citing works

Minimization of drug interactions in polypharmacy treatments of diabetes mellitus type 2 with cardiovascular comorbidities by using the decision support tool PM-TOM

Kulenović, A., & Lagumdzija-Kulenovic, A. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101267 · Cited by 2 · see citing works

Factors Associated With the Development of Dyslipidemia Among Pediatric Patients With Diabetes: A Single-centre–based Study

Alshammri, F., Geddie, H., Sawalha, N. A., Kim, G. Y., McAssey, K., & Morrison, K. M. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.06.003 · Cited by 2 · see citing works

Association between low-carbohydrate-diet score, glycemia and cardiovascular risk factors in adults with type 1 diabetes

Nguyen, É., Wong, K. D., Lalanne‐Mistrih, M., RABASA-LHORET, R. P. R., & Brazeau, A. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.04.014 · Cited by 2 · see citing works

Care Endpoints in Adults With Type 2 Diabetes: Screening and Therapeutic Targets at a Canadian Tertiary Diabetes Care Centre

Pasqua, M., Hu, X. W., Tardio, V., & Tsoukas, M. A. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2022.07.002 · Cited by 3 · see citing works

Oculomics of lipid metabolism: A scoping review across anterior and posterior segment diseases

Kim, H., Joe, B. H., Nam, D., & Yoo, T. K. (2026) · Science Progress · doi:10.1177/00368504261453276 · Cited by 1 · see citing works

Comparison of the effectiveness and safety between gabapentin and amitriptyline in pain improvement in peripheral diabetic neuropathy patients: a review

Rachmania, N., Probosuseno, P., & Rahmawati, F. (2024) · Indonesian Journal of Pharmacology and Therapy · doi:10.22146/ijpther.10307 · Cited by 1 · see citing works

Lower achievement of guideline recommended care in Canadian adults with early-onset diabetes: A population-based cohort study

Sriskandarajah, A., Metcalfe, A., Nerenberg, K. A., & Butalia, S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111756 · Cited by 1 · see citing works

Changes in Target Achievement Rates after Statin Prescription Changes at a Single University Hospital

Choe, S., Shinn, J., Kim, H., & Kim, J. H. (2020) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2020.2.e14 · Cited by 1 · see citing works

Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?

Deed, G., Atherton, J. J., dʼEmden, M. C., Rasalam, R. R., Sharma, A. K., & Sindone, A. P. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0663-x

Atteinte des cibles thérapeutiques pour le diabète de type 2 en 2015 et 2020 en médecine de soins primaires au Canada

Nandiwada, S., Manca, D. P., Yeung, R. O., & Lau, D. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.220673-f

Potensi Jus Kombinasi Daging Kelapa (Cocos nucifera) dan Daging Putih Semangka (Citrullus lanatus) sebagai Modalitas Preventif Dislipidemia

Afifudin, H. H., Fajar, M. M., Budiyanto, M. H. A. A., Rahmatullah, D. C. D., Widyadhana, A. D., Linuwih, P. U., Rakhmanto, A. W., & Pramaningtyas, M. D. (2023) · Amerta Nutrition · doi:10.20473/amnt.v7i2.2023.279-282

Addiction habits in a rural cohort of injection drug users and effects on serum lipid profile: Analysis of a repeated measures study from an eastern state of India

Lahiri, A., Jha, S. S., & Chakraborty, A. (2024) · The National Medical Journal of India · doi:10.25259/nmji_1_21

Paleolithic Diet and Dyslipidemia

Omrani, M., & Rahideh, S. T. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.112186

Additional file 2 of Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study

Hao, R. C., Myroniuk, T., McGuckin, T., Manca, D., Campbell-Scherer, D., Lau, D., & Yeung, R. O. (2022) · Figshare · doi:10.6084/m9.figshare.19844664

Additional file 2 of Diabetic dyslipidemia and its predictors among people with diabetes in Ethiopia: systematic review and meta-analysis

Azagew, A. W., Abate, H. K., Mekonnen, C. K., Mekonnen, H. S., Tezera, Z. B., & Belay, G. J. (2024) · Figshare · doi:10.6084/m9.figshare.26752168

Additional file 3 of Diabetic dyslipidemia and its predictors among people with diabetes in Ethiopia: systematic review and meta-analysis

Azagew, A. W., Abate, H. K., Mekonnen, C. K., Mekonnen, H. S., Tezera, Z. B., & Belay, G. J. (2024) · Figshare · doi:10.6084/m9.figshare.26752171

Additional file 1 of Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study

Hao, R. C., Myroniuk, T., McGuckin, T., Manca, D., Campbell-Scherer, D., Lau, D., & Yeung, R. O. (2022) · Figshare · doi:10.6084/m9.figshare.19844661

Additional file 1 of Diabetic dyslipidemia and its predictors among people with diabetes in Ethiopia: systematic review and meta-analysis

Azagew, A. W., Abate, H. K., Mekonnen, C. K., Mekonnen, H. S., Tezera, Z. B., & Belay, G. J. (2024) · Figshare · doi:10.6084/m9.figshare.26752165

Evaluating Virtual Care for Adults with Type 2 Diabetes During the COVID-19 Pandemic: Results From a Pre–Post Retrospective Cohort Pilot Study in a Canadian Family Health Team

Freeman, K., Tamale, J., Tamale, E., & Salerno, J. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.12.010

Phytochemical analysis, toxicity studies, and evaluation of the antidiabetic and antioxidant potential of Globimetula cupulata (DC) Van Tieghem leaf extracts in streptozotocin-induced diabetic rats

Hamadjida, A., Essono, S. M., Miaffo, D., Nkono, B. L. N. Y., Tchoupou, R. N., Ntchapda, F., & Mbomo, R. E. A. (2026) · Next research. · doi:10.1016/j.nexres.2026.101344

Effectiveness of Group Medical Visits on Cardiometabolic Outcomes in Adult Patients With Cardiometabolic Diseases: An Umbrella Review

Couturier, S., Déry, V., Plourde Roussel, P., É., L., Faivre, P., Cormier, J., Aubé, S., Gallant, F., O'Brien, M. W., Mekari, S., et al. (2026) · Lifestyle Medicine · doi:10.1002/lim2.70080

Diabetic dyslipidemia Prevalence and its Predictors among People with Diabetes in Ethiopia: Systematic Review and Meta-Analysis

Azagew, A. W., Abate, H. K., Mekonnen, C. K., Mekonnen, H. S., Tezera, Z. B., & Belay, G. J. (2024) · ASRIC Journal on Health Sciences · doi:10.68327/wlfx9040

Rationale and Design of a Parallel Randomized Trial of a DASH‐Enhanced Portfolio Diet With or Without Ultra‐Processed Plant Proteins for Blood Pressure and Other Cardiometabolic Risk Factors in Adults With Hypertension and Obesity: The Substitution of High With Low Ultra‐Processed Soy Protein Foods in a Guideline‐Based Diet Intervention on Cardiometabolic Health Trial

Houshialsadat, Z., Viscardi, G., Rossi, A., Ayoub‐Charette, S., Chaar, D. E., McKay, B. M., Symington, A. M., Kavanagh, M. E., Erlich, M. N., de Souza, R. J., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049902

Management of Diabetic Dyslipidemia

Del, M., Solano, P., Goldberg, R. B., & Endocrinol Metab Clin, N. (2014)

Lipid Management in Type 2 Diabetes

Solano, M. P., & Goldberg, R. B. (2006) · Clinical Diabetes · doi:10.2337/diaclin.24.1.27 · Cited by 80 · see citing works

Lipids and lipid management in diabetes

Jaiswal, M., Schinske, A., & Pop‐Busui, R. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.12.001 · Cited by 117 · see citing works

Lipid Management in Patients With Diabetes

Inzucchi, S. E., & Amatruda, J. M. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1309 · Cited by 12 · see citing works

Managing Dyslipidemia in Type 2 Diabetes

Nelson, A. J., Rochelau, S. K., & Nicholls, S. J. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.004 · Cited by 38 · see citing works